Cutaneous Adverse Events of Targeted Anticancer Therapy: A Review of Common Clinical Manifestations and Management

December 2015 in “ DOAJ (DOAJ: Directory of Open Access Journals) ”

Pei‐Han Kao, Jen‐Shi Chen, Wen‐Hung Chung, Rosaline Chung‐Yee Hui, Chih-Hsun Yang

Studysummary This study reports that targeted anticancer therapies frequently cause skin-related side effects, which may impact patient adherence and quality of life, but these effects are positively correlated with treatment response.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on doaj.org →

Discuss this study in the Community →

Research cited in this study

6 / 6 results

research Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management

68 citations , January 2014 in “Dermatology research and practice”

This review discusses the presentation and management of skin toxicity from epidermal growth factor inhibitors, highlighting a correlation between cutaneous adverse effects and tumor response, but reports no new clinical results.

research Dermatologic Adverse Events Associated With Afatinib: An Oral ErbB Family Blocker

87 citations , March 2013 in “Expert Review of Anticancer Therapy”

This article summarizes dermatologic adverse events in patients treated with afatinib in clinical trials and discusses strategies for managing these side effects, without providing new clinical results.

research A Case Report of Inflammatory Nonscarring Alopecia Associated with the Epidermal Growth Factor Receptor Inhibitor Erlotinib

33 citations , June 2009 in “Journal of Cutaneous Pathology”

This article discusses the cutaneous side effects of erlotinib, an EGFR inhibitor, in a patient with non-small cell lung cancer, reporting nonscarring alopecia and indicative scalp biopsy findings.

research Nonscarring Inflammatory Alopecia Associated With the Epidermal Growth Factor Receptor Inhibitor Gefitinib

57 citations , August 2006 in “Journal of the American Academy of Dermatology”

This case report describes a woman who developed extensive nonscarring inflammatory hair loss after two years of gefitinib treatment, highlighting potential cutaneous side effects associated with epidermal growth factor receptor blockers.

research Cutaneous Side Effects in Non-Small Cell Lung Cancer Patients Treated with Iressa (ZD1839), an Inhibitor of Epidermal Growth Factor

116 citations , December 2003 in “Acta Dermato Venereologica”

This study reports that Iressa, an anti-cancer agent, commonly causes acneiform eruptions and xerosis as cutaneous side effects, similar to other agents targeting epidermal growth factor receptors.

research Follicular and Epidermal Alterations in Patients Treated with ZD1839 (Iressa), an Inhibitor of the Epidermal Growth Factor Receptor

169 citations , September 2002 in “British journal of dermatology/British journal of dermatology, Supplement”

This study reports that ZD1839 (Iressa), an anticancer drug, was associated with acneiform eruptions and hair growth abnormalities due to its inhibition of epidermal growth factor receptor signaling in the skin.